A Phase 2 clinical trial of PTG-007 in presymptomatic Type-1 Diabetes.

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 28 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 Oct 2024 Status changed from planning to not yet recruiting.
24 Oct 2024 Planned number of patients changed to 150.
24 Oct 2024 According to PolTREG Media Release, company launched a placebo-controlled Phase 2 clinical trial with PTG-007 Treg cell therapy in presymptomatic type-1 diabetes (T1D) patients, after receiving approval from the European Medicines Agency.Clinical sites for the study have started to open, and patient recruitment and randomization will follow later this year.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com